Across TCGA pan-cancer cohorts, FAM166A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM166A data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FAM166A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM166A expression acts as an unfavorable survival marker.

LUAD and PRAD are the cancer types where FAM166A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.053	0.835	<.001	42	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: FAM166A tumor-vs-normal RNA expression · all FAM166A data types